bluuebunny/crossref_metadata_2025_split huggingface dataset:
Two- and Three-Dimensional Relationships Between Knee and Hip Kinematic Motion Analysis: Single-Leg Drop-Jump Landings
Authors: Sorenson Bryan , Kernozek Thomas W. , Willson John David , Ragan Robert , Hove Jordan 
Published: February 2015

Context:Hip- and knee-joint kinematics during drop landings are relevant to lower-extremity injury mechanisms. In clinical research the “gold standard” for joint kinematic assessment is 3-dimensional (3D) motion analysis. However, 2-dimensional (2D) kinematic analysis is an objective and feasible alternative.Objective:To quantify the relationship between 2D and 3D hip and knee kinematics in single-leg drop landings and test for a set of 3D hip and knee kinematics that best predicts 2D kinematic measures during single-leg drop landings Design: Descriptive, comparative laboratory study.Participants:31 healthy college-age women (65.5 kg [SD 12.3], 168.1 cm [SD 6.7]).Methods:Participants performed five 40-cm single-leg landings during motion capture at 240 Hz. Multiple regressions were used to predict relationships for knee and hip between 2D frontal-plane projection angles (FPPA) and 3D measurements.Results:2D knee FPPA had a strong relationship with 3D frontal-plane knee kinematics at initial contact (IC) (r2 = .72), which was only minimally improved with the addition of knee sagittal-plane and hip transverse-plane positions at IC (r2 = .77). In contrast, 2D knee FPPA had a low relationship with 3D knee-abduction excursion (r2 = .06). The addition of knee sagittal-plane and hip transverse-plane motions did not improve this relationship (r2 = .14). 2D hip FPPA had a moderate relationship with 3D frontal-plane hip position at IC (r2 = .52), which was strengthened with the addition of hip sagittal-plane position (r2 = .60). In addition, hip 2D FPPA into adduction excursion had a strong association with 3D hip-adduction excursion (r2 = .70).Conclusion:2D kinematics can predict 3D frontal-plane hip and knee position at IC during a single-leg landing but predict 3D frontal-plane knee excursion with far less accuracy.
Genome Sequences of Two Pandoraea pnomenusa Isolates Recovered 11 Months Apart from a Cystic Fibrosis Patient
Authors: Ee Robson , Ambrose Mark , Lazenby James , Williams Paul , Chan Kok-Gan , Roddam Louise 
Published: February 2015

ABSTRACT

Pandoraea is an emerging respiratory pathogen capable of causing chronic lung infections in people with cystic fibrosis (CF), but the clinical significance of this infection is ambiguous. We have sequenced and annotated the genomes of two multidrug-resistant
Pandoraea pnomenusa
isolates recovered 11 months apart from the same CF patient.
Draft Genome Sequences of the Enteroinvasive Escherichia coli Strains M4163 and 4608-58
Authors: Leonard Susan R. , Lacher David W. , Lampel Keith A. 
Published: February 2015

ABSTRACT

We report here the draft genome sequences of enteroinvasive
Escherichia coli
(EIEC) O124:H30 strain M4163 isolated from imported French cheese and EIEC O143:H26 strain 4608-58. The assembled data determined that both strains contain multiple copies of the
ipaH
gene, as well as the pINV A form of the invasion plasmid.
Draft Genome Sequence of Acinetobacter oleivorans PF1, a Diesel-Degrading and Plant-Growth-Promoting Endophytic Strain Isolated from Poplar Trees Growing on a Diesel-Contaminated Plume
Authors: Gkorezis Panagiotis , Rineau Francois , Van Hamme Jonathan , Franzetti Andrea , Daghio Matteo , Thijs Sofie , Weyens Nele , Vangronsveld Jaco 
Published: February 2015

ABSTRACT
We report the 3.7-Mb draft genome of Acinetobacter oleivorans strain PF1, a hydrocarbonoclastic Gram-negative bacterium in the class Gammaproteobacteria, isolated from poplar trees growing on a diesel-contaminated plume at the Ford Motor Company site in Genk, Belgium. Strain PF1 is a potent plant-growth promoter, useful for diesel fuel phytoremediation applications.
Draft Genome Sequence of High-Temperature-Adapted Protochlamydia sp. HS-T3, an Amoebal Endosymbiotic Bacterium Found in Acanthamoeba Isolated from a Hot Spring in Japan
Authors: Yamaguchi Hiroyuki , Matsuo Junji , Yamazaki Tomohiro , Ishida Kasumi , Yagita Kenji 
Published: February 2015

ABSTRACT
Here, we report the draft genome sequence of high-temperature-adapted Protochlamydia sp. strain HS-T3, an environmental chlamydia. This bacterium is an amoebal endosymbiont, found in Acanthamoeba isolated from a hot spring in Japan. Strain HS-T3 readily grew in mammalian cells at 37°C, a characteristic not previously reported for environmental chlamydiae.
Draft Genome Sequence of Streptomyces sp. Strain CT34, Isolated from a Ghanaian Soil Sample
Authors: Zhai Yin , Cheng Bin , Hu Juan , Kyeremeh Kwaku , Wang Xiaoling , Jaspars Marcel , Deng Hai , Deng Zi-Xin , Hong Kui 
Published: February 2015

ABSTRACT
Presented here is a draft genome sequence of Streptomyces sp. strain CT34, which produces a novel ribosomally synthesized and posttranslationally modified peptide (RiPP). Analysis of the deduced open reading frame set identified the putative RiPP biosynthesis gene cluster, as well as other secondary metabolite gene clusters.
Draft Genome Sequences of Five New Strains of Methylophilaceae Isolated from Lake Washington Sediment
Authors: McTaggart Tami L. , Benuska Gabrielle , Shapiro Nicole , Woyke Tanja , Chistoserdova Ludmila 
Published: February 2015

ABSTRACT
We sequenced the genomes of five new Methylophilaceae strains isolated from Lake Washington sediment. We used the new sequences to sort these new strains into specific Methylophilaceae ecotypes, including one novel ecotype. The new genomes expand the known diversity of Methylophilaceae and provide new models for studying the ecology of methylotrophy.
Complete Genome Sequences of a Mycobacterium smegmatis Laboratory Strain (MC
2
155) and Isoniazid-Resistant (4XR1/R2) Mutant Strains
Authors: Mohan Abhilash , Padiadpu Jyothi , Baloni Priyanka , Chandra Nagasuma 
Published: February 2015

ABSTRACT

We report the whole genome sequences of a
Mycobacterium smegmatis
laboratory wild-type strain (MC
2
155) and mutants (4XR1, 4XR2) resistant to isoniazid. Compared to
Mycobacterium smegmatis
MC
2
155 (NC_008596), a widely used strain in laboratory experiments, the MC
2
155, 4XR1, and 4XR2 strains are 60, 128 and 93 bp longer, respectively.
Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H3N6, Isolated from a Domestic Pigeon in Guangxi, Southern China
Authors: Liu Tingting , Xie Zhixun , Wang Guoli , Song Degui , Huang Li , Xie Zhiqing , Deng Xianweng , Luo Sisi , Huang Jiaoling , Zeng Tingting 
Published: February 2015

ABSTRACT
The H3 subtype of avian influenza virus can provide genes for human influenza virus through gene reassortment, which has raised great concerns about its potential threat to human health. An H3N6 subtype of avian influenza virus was isolated from Guangxi Province, China, in 2009. All eight gene segments of the strain were sequenced. The sequence analysis indicated that this H3N6 virus was a nature reassortant virus. The genome sequences now can be used to understand the epidemiological and molecular characteristics of the H3N6 influenza virus in southern China.
Automatic Pharynx Segmentation from MRI Data for Analysis of Sleep Related Disorders
Authors: Ivanovska Tatyana , Laqua René , Shahid Muhammad Laiq , Linsen Lars , Hegenscheid Katrin , Völzke Henry 
Published: February 2015

In our project, we analyse throat structures using magnetic resonance imaging (MRI) to associate anatomic risk factors with sleep related disorders. Pharynx segmentation is the first step in the three-dimensional analysis of throat tissues.We present a pipeline for automatic pharynx segmentation. The automatic part of the approach consists of three steps: smoothing, thresholding, 2D and 3D connected component analysis. Whereas two first steps are rather common, the third step provides a set of general rules for the automatic extraction of the pharyngeal component. Our method requires less than one minute to extract the pharyngeal structures. The approach is evaluated quantitatively on 30 data sets using region-based and edge-based measures.
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Authors: Weller Michael , Tabatabai Ghazaleh , Kästner Bärbel , Felsberg Jörg , Steinbach Joachim P. , Wick Antje , Schnell Oliver , Hau Peter , Herrlinger Ulrich , Sabel Michael C. , Wirsching Hans-Georg , Ketter Ralf , Bähr Oliver , Platten Michael , Tonn Jörg C. , Schlegel Uwe , Marosi Christine , Goldbrunner Roland , Stupp Roger , Homicsko Krisztian , Pichler Josef , Nikkhah Guido , Meixensberger Jürgen , Vajkoczy Peter , Kollias Spyros , Hüsing Johannes , Reifenberger Guido , Wick Wolfgang 
Published: February 2015

Abstract
Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen.
Experimental Design: Patients with glioblastoma at first progression after TMZ/RT→TMZ and at least two maintenance temozolomide cycles were randomized to Arm A [one week on (120 mg/m2 per day)/one week off] or Arm B [3 weeks on (80 mg/m2 per day)/one week off]. The primary endpoint was median time-to-treatment failure (TTF) defined as progression, premature temozolomide discontinuation for toxicity, or death from any cause. O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was prospectively assessed by methylation-specific PCR.
Results: Because of withdrawal of support, the trial was prematurely closed to accrual after 105 patients. There was a similar outcome in both arms for median TTF [A: 1.8 months; 95% confidence intervals (CI), 1.8–3.2 vs. B: 2.0 months; 95% CI, 1.8–3.5] and overall survival [A: 9.8 months (95% CI, 6.7–13.0) vs. B: 10.6 months (95% CI, 8.1–11.6)]. Median TTF in patients with MGMT-methylated tumors was 3.2 months (95% CI, 1.8–7.4) versus 1.8 months (95% CI, 1.8–2) in MGMT-unmethylated glioblastoma. Progression-free survival rates at 6 months (PFS-6) were 39.7% with versus 6.9% without MGMT promoter methylation.
Conclusions: Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma. Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation. Clin Cancer Res; 21(9); 2057–64. ©2015 AACR.
Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
Authors: Leonard John E. , Fisher Terrence L. , Winter Laurie A. , Cornelius Chad A. , Reilly Christine , Smith Ernest S. , Zauderer Maurice 
Published: February 2015

Abstract
The humanized IgG4 monoclonal antibody VX15/2503 bound with 1 to 5 nmol/L affinity to purified recombinant semaphorin 4D (SEMA4D; CD100) produced using murine, rat, cynomolgus macaque, and human sequences. The affinity for native SEMA4D expressed on macaque T lymphocytes was approximately 0.6 nmol/L. Tissues from rats and cynomolgus macaques demonstrated specific staining only with resident lymphocytes. Single-dose and one-month toxicology/PK studies used VX15/2503 dose levels of 0 to 100 mg/kg. No toxicity was observed with either species in these studies, thus the no observed adverse effect level (NOAEL) was 100 mg/kg. Cmax, exposure, and half-life values were similar for both rats and macaques. The NOAEL in a primate maximum feasible dose study was 200 mg/kg. Saturation of T-cell–associated SEMA4D occurred following administration of single doses of 0.1 mg/kg and above; five weekly injections of VX15/2503 at a dose level of 100 mg/kg produced saturation lasting for more than 120 and 130 days, respectively, for rats and primates. Macaques administered five weekly doses of VX15/2503 showed dose-dependent reductions of 2- to 3-fold in T-cell SEMA4D (cSEMA4D) expression levels compared with controls. Reduced cSEMA4D expression levels continued until serum antibody concentrations were 2 to 5 μg/mL, and thereafter normal cSEMA4D levels were restored. On the basis of these data, a phase I clinical study of the safety and tolerability of VX15/2503 was conducted, enrolling adult patients with advanced solid tumor diseases; a single-dose, dose escalation, phase I safety study was also initiated with subjects with multiple sclerosis. Mol Cancer Ther; 14(4); 964–72. ©2015 AACR.
Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma
Authors: Wikoff William R. , Grapov Dmitry , Fahrmann Johannes F. , DeFelice Brian , Rom William N. , Pass Harvey I. , Kim Kyoungmi , Nguyen UyenThao , Taylor Sandra L. , Gandara David R. , Kelly Karen , Fiehn Oliver , Miyamoto Suzanne 
Published: February 2015

AbstractAdenocarcinoma, a type of non–small cell lung cancer, is the most frequently diagnosed lung cancer and the leading cause of lung cancer mortality in the United States. It is well documented that biochemical changes occur early in the transition from normal to cancer cells, but the extent to which these alterations affect tumorigenesis in adenocarcinoma remains largely unknown. Herein, we describe the application of mass spectrometry and multivariate statistical analysis in one of the largest biomarker research studies to date aimed at distinguishing metabolic differences between malignant and nonmalignant lung tissue. Gas chromatography time-of-flight mass spectrometry was used to measure 462 metabolites in 39 malignant and nonmalignant lung tissue pairs from current or former smokers with early stage (stage IA–IB) adenocarcinoma. Statistical mixed effects models, orthogonal partial least squares discriminant analysis and network integration, were used to identify key cancer-associated metabolic perturbations in adenocarcinoma compared with nonmalignant tissue. Cancer-associated biochemical alterations were characterized by (i) decreased glucose levels, consistent with the Warburg effect, (ii) changes in cellular redox status highlighted by elevations in cysteine and antioxidants, alpha- and gamma-tocopherol, (iii) elevations in nucleotide metabolites 5,6-dihydrouracil and xanthine suggestive of increased dihydropyrimidine dehydrogenase and xanthine oxidoreductase activity, (iv) increased 5′-deoxy-5′-methylthioadenosine levels indicative of reduced purine salvage and increased de novo purine synthesis, and (v) coordinated elevations in glutamate and UDP-N-acetylglucosamine suggesting increased protein glycosylation. The present study revealed distinct metabolic perturbations associated with early stage lung adenocarcinoma, which may provide candidate molecular targets for personalizing therapeutic interventions and treatment efficacy monitoring. Cancer Prev Res; 8(5); 410–8. ©2015 AACR.
Metabolic Syndrome Individuals With and Without Type 2 Diabetes Mellitus Present Generalized Vascular Dysfunction
Authors: Walther Guillaume , Obert Philippe , Dutheil Frédéric , Chapier Robert , Lesourd Bruno , Naughton Geraldine , Courteix Daniel , Vinet Agnès 
Published: February 2015

Objectives—
The first objective of this study was to demonstrate differences within endothelial-dependent and endothelial-independent vasoreactivity in macro- and microcirculation beds among patients with metabolic syndrome (MetS) with and without type 2 diabetes mellitus (T2D) compared with healthy counterparts. The second objective was to determine relationships among the function of macro- and microvascular systems and abdominal adiposity, as well as inflammatory markers in the 3 groups.

Approach and Results—
Cross-sectional analyses of 53 patients with MetS without T2D and 25 with T2D, as well as aged 40 years and sex-matched healthy controls included microvascular (cutaneous blood flow measured with laser Doppler flowmetry in response to iontophoresis of acetylcholine and sodium nitroprusside), and macrovascular reactivity (flow-mediated dilation and nitrate-mediated dilation) along with anthropometric measures, plasma glucose, and insulin and inflammatory markers. Compared with controls, MetS participants showed depressed endothelial function of both micro- and macrocirculation beds. T2D in patients with MetS revealed an exacerbated vascular smooth muscle dysfunction in micro- and macrocirculation compared with MetS without T2D. Indices of micro- and macrocirculation were predominantly inversely related to abdominal fat and inflammatory markers.

Conclusions—
MetS was associated with endothelial-dependent and endothelial-independent dysfunction, affecting both the macro- and the microvascular systems. Participants with diabetes mellitus demonstrated the most severe smooth muscle dysfunction. The presence of central abdominal fat and systemic inflammation seems implicated in the pathogenesis of vascular dysfunctions in MetS.
Nanoparticle-Mediated Expression of a Wnt Pathway Inhibitor Ameliorates Ocular Neovascularization
Authors: Wang Zhongxiao , Cheng Rui , Lee Kyungwon , Tyagi Puneet , Ding Lexi , Kompella Uday B. , Chen Jing , Xu Xun , Ma Jian-xing 
Published: February 2015

Objective—
The deficiency of very low-density lipoprotein receptor resulted in Wnt signaling activation and neovascularization in the retina. The present study sought to determine whether the very low-density lipoprotein receptor extracellular domain (VLN) is responsible for the inhibition of Wnt signaling in ocular tissues.

Approach and Results—

A plasmid expressing the soluble VLN was encapsulated with poly(lactide-co-glycolide acid) to form VLN nanoparticles (VLN-NP). Nanoparticles containing a plasmid expressing the low-density lipoprotein receptor extracellular domain nanoparticle were used as negative control. MTT, modified Boyden chamber, and Matrigel (™) assays were used to evaluate the inhibitory effect of VLN-NP on Wnt3a-stimulated endothelial cell proliferation, migration, and tube formation.
Vldlr
−/−
mice, oxygen-induced retinopathy, and alkali burn–induced corneal neovascularization models were used to evaluate the effect of VLN-NP on ocular neovascularization. Wnt reporter mice (BAT-gal), Western blotting, and luciferase assay were used to evaluate Wnt pathway activity. Our results showed that VLN-NP specifically inhibited Wnt3a-induced endothelial cell proliferation, migration, and tube formation. Intravitreal injection of VLN-NP inhibited abnormal neovascularization in
Vldlr
−/−
, oxygen-induced retinopathy, and alkali burn–induced corneal neovascularization models, compared with low-density lipoprotein receptor extracellular domain nanoparticle. VLN-NP significantly inhibited the phosphorylation of low-density lipoprotein receptor-related protein 6, the accumulation of β-catenin, and the expression of vascular endothelial growth factor in vivo and in vitro.

Conclusions—
Taken together, these results suggest that the soluble VLN is a negative regulator of the Wnt pathway and has antiangiogenic activities. Nanoparticle-mediated expression of VLN may thus represent a novel therapeutic approach to treat pathological ocular angiogenesis and potentially other vascular diseases affected by Wnt signaling.
Neuron-Derived Neurotrophic Factor Ameliorates Adverse Cardiac Remodeling After Experimental Myocardial Infarction
Authors: Joki Yusuke , Ohashi Koji , Yuasa Daisuke , Shibata Rei , Kataoka Yoshiyuki , Kambara Takahiro , Uemura Yusuke , Matsuo Kazuhiro , Hayakawa Satoko , Hiramatsu-Ito Mizuho , Kanemura Noriyoshi , Ito Masanori , Ogawa Hayato , Daida Hiroyuki , Murohara Toyoaki , Ouchi Noriyuki 
Published: February 2015

Background—
Myocardial infarction (MI) is one of the major causes of death worldwide. Chronic heart failure is a serious complication of MI that leads to poor prognosis. We recently found that neuron-derived neurotrophic factor (NDNF) is a proangiogenic secretory protein that is upregulated in ischemic skeletal muscle. Here, we examined whether NDNF modulates cardiac remodeling in response to chronic ischemia.

Methods and Results—
C57BL/6J wild-type mice were subjected to the permanent ligation of the left anterior descending coronary artery to create MI. Adenoviral vectors expressing NDNF or β-galactosidase (control) were intramuscularly injected into mice 3 days before permanent left anterior descending coronary artery ligation. Intramuscular administration of adenoviral vectors expressing NDNF to mice resulted in increased levels of circulating NDNF. Adenoviral vectors expressing NDNF administration improved left ventricular systolic dysfunction and dilatation after MI surgery. Moreover, adenoviral vectors expressing NDNF enhanced capillary formation and reduced cardiomyocyte apoptosis and hypertrophy in the post-MI hearts. Treatment of cultured cardiomyocytes with recombinant NDNF protein led to reduced apoptosis under conditions of hypoxia. NDNF also promoted the phosphorylation of Akt and focal adhesion kinase in cardiomyocytes. Blockade of focal adhesion kinase activation blocked the stimulatory effects of NDNF on cardiomyocyte survival and Akt phosphorylation. Similarly, treatment of cultured endothelial cells with NDNF protein led to enhancement of network formation and Akt phosphorylation, which was diminished by focal adhesion kinase inhibition.

Conclusions—
These data suggest that NDNF ameliorates adverse myocardial remodeling after MI by its abilities to enhance myocyte survival and angiogenesis in the heart through focal adhesion kinase/Akt-dependent mechanisms.
Comparative Effectiveness and Safety of a Catheterization Laboratory–Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention
Authors: Gurm Hitinder S. , Hosman Carrie , Bates Eric R. , Share David , Hansen Ben B. 
Published: February 2015

Background—
Eptifibatide, a small-molecule glycoprotein IIb/IIIa inhibitor, is conventionally administered as a bolus plus infusion. A growing number of clinicians are using a strategy of catheterization laboratory–only eptifibatide (an off-label use) as procedural pharmacotherapy for patients undergoing percutaneous coronary intervention although the comparative effectiveness of this approach is unknown.

Methods and Results—

We compared the in-hospital outcome of patients undergoing percutaneous coronary intervention across 47 hospitals and treated with eptifibatide bolus plus infusion with those treated with a catheterization laboratory–only regimen. We used optimal matching to link the use of catheterization laboratory–only eptifibatide with clinical outcomes, including mortality, myocardial infarction, bleeding, and need for transfusion. Of the 84 678 percutaneous coronary interventions performed during 2010 to 2011, and meeting our inclusion criteria, eptifibatide was administered to 21 296 patients. Of these, a catheterization laboratory–only regimen was used in 4511 patients, whereas 16 785 patients were treated with bolus plus infusion. In the optimally matched analysis, compared with bolus plus infusion, a catheterization laboratory–only regimen was associated with a reduction in bleeding (optimally matched adjusted odds ratio, 0.74; 95% confidence interval, 0.58–0.93;
P
=0.014) and need for transfusion (optimally matched adjusted odds ratio, 0.70; 95% confidence interval, 0.52–0.92;
P
=0.012), with no difference in mortality or myocardial infarction.

Conclusions—
A catheterization laboratory–only eptifibatide regimen is commonly used in clinical practice and is associated with a significant reduction in bleeding complications in patients undergoing contemporary percutaneous coronary intervention.